These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 9218101

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 23. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
    Gilbert HS.
    Cancer; 1998 Sep 15; 83(6):1205-13. PubMed ID: 9740087
    [Abstract] [Full Text] [Related]

  • 24. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
    Elliott MA, Tefferi A.
    Semin Thromb Hemost; 1997 Sep 15; 23(5):463-72. PubMed ID: 9387205
    [Abstract] [Full Text] [Related]

  • 25. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
    Antelo ML, de Las Heras N, Gonzalez Porras JR, Kerguelen A, Raya JM.
    Expert Rev Hematol; 2015 Dec 15; 8(6):819-35. PubMed ID: 26368319
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D, Mascarenhas J.
    Curr Opin Hematol; 2016 Mar 15; 23(2):150-60. PubMed ID: 26717193
    [Abstract] [Full Text] [Related]

  • 28. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S.
    Lancet Haematol; 2020 Mar 15; 7(3):e226-e237. PubMed ID: 31982039
    [Abstract] [Full Text] [Related]

  • 29. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
    Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F.
    Ann Intern Med; 2003 Sep 16; 139(6):470-5. PubMed ID: 13679323
    [Abstract] [Full Text] [Related]

  • 30. How to Treat Essential Thrombocythemia and Polycythemia Vera.
    Besses C, Alvarez-Larrán A.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 16; 16 Suppl():S114-23. PubMed ID: 27521307
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
    Vannucchi AM, Guglielmelli P.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):480-488. PubMed ID: 29222296
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P.
    Semin Thromb Hemost; 2006 Jun 08; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [Abstract] [Full Text] [Related]

  • 35. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.
    Petitt RM, Silverstein MN, Petrone ME.
    Semin Hematol; 1997 Jan 08; 34(1):51-4. PubMed ID: 9025162
    [No Abstract] [Full Text] [Related]

  • 36. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Jun 08; 88(6):507-16. PubMed ID: 23695894
    [Abstract] [Full Text] [Related]

  • 37. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group.
    Leuk Res; 2005 May 08; 29(5):481-91. PubMed ID: 15755500
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep 08; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.